Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug
Amgen $AMGN and its Belgian partners at UCB may have won over the FDA, but the EMA is still not convinced by their bone-building osteoporosis drug romosozumab.
On Friday, the companies disclosed that the European regulator had adopted a negative opinion on the drug, branded Evenity, for the treatment of osteoporosis in men and in postmenopausal women at increased risk of fracture. The partners plan to appeal the decision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.